GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Galderma Group AG (XSWX:GALD) » Definitions » Net Income (Continuing Operations)

Galderma Group AG (XSWX:GALD) Net Income (Continuing Operations) : CHF42 Mil (TTM As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Galderma Group AG Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Galderma Group AG's Net Income (Continuing Operations) for the six months ended in Jun. 2024 was CHF42 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2024 was CHF42 Mil.

Galderma Group AG Net Income (Continuing Operations) Historical Data

The historical data trend for Galderma Group AG's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galderma Group AG Net Income (Continuing Operations) Chart

Galderma Group AG Annual Data
Trend
Net Income (Continuing Operations)

Galderma Group AG Semi-Annual Data
Jun23 Jun24
Net Income (Continuing Operations) 3.60 42.01

Galderma Group AG Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF42 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galderma Group AG  (XSWX:GALD) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Galderma Group AG Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Galderma Group AG's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Galderma Group AG Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Galderma Group AG (XSWX:GALD) » Definitions » Net Income (Continuing Operations)
Comparable Companies
XSWX:SDZ XSWX:SFZN XSWX:PPGN XSWX:CURN ZTS XTER:MRK NSE:SUNPHARMA LSE:HLN TSE:4502 XTAE:TEVA NSE:DIVISLAB VTRS SZSE:000538 NBIX BOM:543904 BOM:500124 NSE:TORNTPHARM HKSE:03692 TSE:4507 BOM:500257
Traded in Other Exchanges
GALDY:USA GDERF:USA GALDz:UK
Address
Zahlerweg 10, Zug, CHE, 6300
Website
https://www.galderma.com
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a standalone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 45% of net sales from the US and employs around 6,600 people.

Galderma Group AG Headlines

No Headlines